PDS Biotechnology’s (PDSB) Buy Rating Reaffirmed at HC Wainwright

PDS Biotechnology (NASDAQ:PDSB)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They presently have a $21.00 target price on the stock.

A number of other research analysts also recently commented on PDSB. Cantor Fitzgerald reiterated an “overweight” rating on shares of PDS Biotechnology in a report on Thursday, May 9th. B. Riley dropped their price target on PDS Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a research note on Wednesday, June 12th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $16.67.

PDS Biotechnology Stock Down 9.3 %

Shares of PDSB traded down $0.33 during mid-day trading on Thursday, reaching $3.23. The company’s stock had a trading volume of 557,905 shares, compared to its average volume of 746,601. PDS Biotechnology has a 12-month low of $2.53 and a 12-month high of $6.85. The stock has a market cap of $118.48 million, a PE ratio of -2.37 and a beta of 1.91. The company has a debt-to-equity ratio of 0.45, a current ratio of 4.56 and a quick ratio of 4.56. The company’s 50 day moving average is $3.25 and its 200 day moving average is $4.02.

PDS Biotechnology (NASDAQ:PDSB) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.07. Equities analysts anticipate that PDS Biotechnology will post -1.46 EPS for the current fiscal year.

Institutional Trading of PDS Biotechnology

A number of hedge funds have recently added to or reduced their stakes in PDSB. SG Americas Securities LLC acquired a new stake in PDS Biotechnology during the 4th quarter worth approximately $52,000. Tower Research Capital LLC TRC grew its stake in shares of PDS Biotechnology by 530.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 9,046 shares of the company’s stock worth $45,000 after purchasing an additional 7,612 shares during the period. Inspirion Wealth Advisors LLC lifted its stake in shares of PDS Biotechnology by 5.5% in the first quarter. Inspirion Wealth Advisors LLC now owns 354,977 shares of the company’s stock valued at $1,406,000 after purchasing an additional 18,383 shares during the period. Kathleen S. Wright Associates Inc. purchased a new stake in PDS Biotechnology during the first quarter worth about $28,000. Finally, Vanguard Group Inc. grew its position in PDS Biotechnology by 5.5% during the first quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock worth $6,288,000 after buying an additional 82,135 shares during the period. 26.84% of the stock is owned by institutional investors and hedge funds.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.